H ypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricle. The clinical manifestations of the disease are dyspnea, angina, and a continuum encompassing lightheadedness, presyncope, syncope, and sudden death. Although HCM often is caused by an identifiable mutation in a gene coding for a sarcomeric protein and inherited in an autosomal-dominant pattern, many patients do not have any relatives in whom the disease is manifest. The prevalence of HCM is estimated to be 0.2%, with Ϸ600 000 Americans affected.
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Several anatomic variants of HCM exist. Of these, hypertrophic obstructive cardiomyopathy (HOCM) is the variant that has been the subject of the most intense investigation. HOCM was previously termed idiopathic hypertrophic subaortic stenosis and is characterized by 4 closely related pathoanatomic features ( Figure 1 ). 1 Obstruction to left ventricular (LV) outflow is caused by bulging of the thickened septum into the left ventricular outflow tract (LVOT) during systole, with apposition of the anterior (occasionally posterior) leaflet of the mitral valve, which demonstrates systolic anterior motion. Mitral regurgitation usually is present, although the degree varies greatly among patients with HOCM.
LVOT gradients may be present at rest or only during Valsalva maneuver or exercise (provocable obstruction). A recent report suggests that if patients with provocable gradients are included, most patients with HCM have the obstructive form of the disease. 2
Management of HCM
The management of HCM may be considered as consisting of 4 elements (Table 1 ). 3 For patients at high risk of sudden death, implantation of a cardioverter-defibrillator is considered. 4 In patients with HOCM, the first line of therapy for symptoms consists of medications with negative inotropic properties that diminish the extent of septal bulging into the LVOT; these are ␤-blockers, calcium channel blockers (of which there has been the largest experience with verapamil), and disopyramide. In most patients, symptoms can be adequately controlled with these medications used alone or in combination. In patients with HOCM and symptoms refractory to optimal medical therapy, mechanical measures aimed at relief of the outflow tract obstruction are considered.
Septal Myectomy
The original mechanical management of patients with HOCM and refractory symptoms consisted of septal myotomy, or simple incision of septal muscle, first performed in 1958. 5, 6 Myotomy was soon replaced by septal myectomy, or removal of septal muscle. 7, 8 In this approach, the surgeon visualizes the thickened septum through an incision in the aortic root and excises a rectangular segment from the basal septum toward the apex. In patients with septal thickness Ͻ15 to 18 mm, septal myectomy incurs a risk of causing a ventricular septal defect; in these cases, an alternative strategy is repair or replacement of the other structure implicated in LVOT obstruction, namely the mitral valve.
Pacing
Dual-chamber pacing with a short atrioventricular delay was suggested as early as 1968 as an innovative approach for the management of HOCM. 9 Although marked beneficial effects of pacing were reported in uncontrolled series, 10 these findings have not been reproduced in randomized controlled trials, 11, 12 although a suggestion exists that a small subset of patients benefits from pacing. 12
Septal Ablation
Transcatheter ablation of the septum with ethanol was first performed at the Royal Brompton Hospital in London in 1994. 13, 14 The first patient to undergo septal ablation had severe symptoms despite ␤-blockade and a resting gradient of 25 mm Hg that increased markedly during the Valsalva maneuver. Peak creatine kinase was 2500 U/L. She was discharged 3 days after septal ablation and was asymptomatic 10 months later. The results were similar for the other 2 patients in the initial report, both of whom also had LVOT gradients that were low at rest and higher in response to provocative maneuvers.
Because the proximal septal branches of the left anterior descending coronary artery supply the conduction system as well as the basal septum, atrioventricular block is a common complication of septal ablation. For this reason, a temporary pacemaker is placed before the procedure. With standard coronary angioplasty guiding catheters, guidewires, and balloon catheters, the most proximal septal branch that can be catheterized is entered, and the angioplasty balloon is inflated. X-ray contrast is injected through the balloon catheter to confirm filling of the septal branch and absence of backflow into the left anterior descending coronary artery itself. Correct catheter placement also is confirmed by myocardial contrast echocardiography (see below). Dehydrated ethanol, usually 1 mL at a time, is then injected slowly through the balloon catheter, causing a targeted myocardial infarction; the usual total dosage of ethanol is 1 to 3 mL. Patients receive narcotics and experience mild to moderate chest pain, usually burning in quality. The gradient can usually be reduced to Ͻ20 mm Hg ( Figure 2 ). In some cases, ethanol is injected selectively into septal subbranches 15 ; in others, it is injected into 2 or 3 septal branches. After delivery of ethanol, distal flow in the affected septal branch is slow or absent (no-reflow phenomenon; see Figure 3 ). 16 Myocardial contrast echocardiography was introduced into the procedure to localize the septal branch supplying the critical septal segment (ie, the point of mitral valve contact and maximal flow acceleration). 17, 18 Myocardial contrast may be achieved with agitated x-ray contrast or an echocardiographic contrast agent. Myocardial contrast echocardiography may identify inappropriate sites for injection of ethanol such as a septal branch supplying myocardium too close to the apex, papillary muscle, inferoposterior LV, or right ventricle. Incorporation of this technique reduces the number of septal branches into which ethanol is injected and may both improve success rate and lower marker release and the need for pacing. 17, 19 Peak creatine kinase is Ϸ500 U/L per 1 mL ethanol injected. In patients with failed septal ablation who subsequently undergo septal myectomy, we have found pathological evidence of necrosis of the vascular endothelium ( Figure  4 ), suggesting that ethanol is toxic to both the coronary circulation and the myocardium. 16 
What Do We Know About the Efficacy and Safety of Septal Myectomy?
Septal myectomy performed by skilled surgeons at highvolume centers results in abolition of the LVOT gradient and relief of symptoms in the great majority of cases (Table 2) . 20 -23 Results in patients with provocable obstruction are comparable to those in patients with resting obstruction. 20 Early mortality, which was high in the early experience with this operation, has been reduced to Յ2% in young or middle-aged otherwise healthy patients undergoing isolated septal myectomy. In older patients, those with comorbid conditions, and those requiring other concomitant cardiac surgery, mortality is considerably higher. 22, 24, 25 Complications of septal myectomy include those peculiar to the operation (eg, ventricular septal defect [1%] 20, 26 and complete heart block for which a permanent pacemaker is required [3% to 10%, lower in the absence of preexisting conduction system disease]), 20 -22,26 and those that pertain to any cardiac operation (eg, postoperative bleeding with tamponade, sepsis, and stroke). 20 -22 Postoperative left bundlebranch block occurs in 40% to 56% of patients. 24, 26, 27 When septal myectomy is successful and uncomplicated, studies with a mean follow-up of 6 to 12 years indicate that the improvement is usually sustained. 20 -22,25,26 Successful septal myectomy results in a decrease in LV mass that is much greater than that attributable to the removal of the septal myocardium itself and that undoubtedly results from relief of pressure overload. 28
What Do We Know About the Efficacy and Safety of Septal Ablation?
Septal ablation performed by skilled operators at highvolume centers results in a marked immediate decrease in LVOT gradient in the great majority of patients. 17,29 -32 In a sizable subset of patients, the gradient response is triphasic, with immediate reduction, early reappearance, and by 3 months after the procedure, sustained fall. 33, 34 This sequence suggests that myocardial stunning may be responsible in large part for the immediate reduction in gradient. After recovery from stunning, ultimate gradient reduction is associated with remodeling of the septum with an increase in LVOT area. 35 Improvement in symptoms occurs over the same 3-month period. Symptom relief and gradient reduction are achieved in Ͼ80% of patients (Table 3) . 32, 36, 37 A clinical impression exists that patients with septal thickness approaching or exceeding 30 mm may not achieve full benefit from septal ablation.
In association with the amelioration of the LVOT gradient, the degree of mitral regurgitation decreases, 17, 29, 38 as does the size of the left atrium. 17, 39 In response to a reduction in the systolic pressure load, systolic myocardial function improves 
Fifer
Septal Myectomy Versus Septal Ablation in the free wall 40 and hypertrophy regresses throughout the LV (as after aortic valve replacement for aortic stenosis; Figure 5 ). 19, 39, 41, 42 Reduction in LVOT gradient and regression of LV hypertrophy are accompanied by improvement in diastolic LV function, 17, 29, 43 which correlates with an increase in exercise capacity. 38 Two studies have demonstrated that, as with septal myectomy, the benefit of septal ablation in patients with provocable gradients is similar to that in patients with resting gradients. 44, 45 These studies provide retrospective support for Sigwart's 13 performance of septal ablation in his first 3 patients, all of whom had provocable obstruction. The standard provocation for deciding whether a patient is a candidate for septal ablation is exercise. Because exercise is not practical in an instrumented patient, patients triaged to ablation on the basis of exercise-induced gradients may receive dobutamine or isoproterenol during the procedure to provide a gradient suitably high to serve as a "target" for ablation.
Temporary complete atrioventricular block occurs during the procedure in approximately half of the patients. 17,29,46 -48 After the procedure, right bundle-branch block is present in approximately half of the patients. 17, 18, 27, 29, 46, 48 A corollary is that patients with preexisting left bundle-branch block usually require permanent pacing after ablation. 48 Another corollary is that patients who undergo sequential septal ablation and septal myectomy (which frequently causes left bundle-branch block) also are likely to require permanent pacing. 49 Although the rate of permanent pacemaker placement was as high as 38% early in the septal ablation experience, 29 it has fallen with the introduction of myocardial contrast echocardiogra-phy and the use of lower dosages of ethanol, with 1 group reporting an incidence of Ͻ10%. 17, 19, 48 In-hospital mortality is 0% to 4%. 19, 29, 30 Deaths have been due to coronary dissection, 30 pulmonary embolism, 17 refractory ventricular fibrillation, 36 right ventricular perforation by the temporary pacemaker, 36 pump failure, 15 and heart block. 29 In-hospital sustained ventricular tachyarrhythmias occur in Ϸ5% of cases. 16 The theoretical concern that after septal ablation, arrhythmic sudden death resulting from superimposition of a myocardial infarction on a cardiomyopathic substrate would be common has fortunately not been realized in clinical practice. In patients with preexisting risk factors for sudden death, an implantable cardioverter-defibrillator may be placed before septal ablation.
Other complications of the procedure are remote myocardial infarction caused by aberrant ethanol injection 14 or collateral circulation 50 and ventricular septal rupture. 19 Because of the latter potential complication, septal ablation should not be performed if septal thickness at the site of planned ethanol delivery is Ͻ15 mm.
Comparison of Septal Ablation and Septal Myectomy
There have been no prospective randomized trials comparing septal ablation with septal myectomy. Investigators have compared the results of septal ablation with those of septal myectomy in several nonrandomized studies (Table 4 ). 49, [51] [52] [53] In none of these retrospective studies have patients been adequately matched for age, gender, and other clinical predictors of outcome in HOCM. In an institution at which both procedures were regularly performed, patients were triaged according to clinical factors, so the groups were not comparable. 49 In particular, the 25 patients undergoing septal ablation were older and had a higher prevalence of comorbid conditions than did the 26 patients undergoing myectomy. At the 3-month follow-up, the gradient reduction was more complete in the surgical cohort, whereas the 2 groups had similar reductions in symptoms, septal thickness, and degree of mitral regurgitation. No deaths occurred in either group.
In the second study from 2 hospitals that each favored 1 of the procedures, patients were triaged according to institutional preference. 51 In this study, it was possible to match patients for age and LVOT gradient. Forty-one patients were included in each group. At the 1-year follow-up, severity of symptoms, maximal oxygen uptake, LVOT gradient, septal thickness, and degree of mitral regurgitation were similar for the 2 therapies. There was 1 death during septal ablation as a result of coronary dissection.
A third study compared the effects of septal ablation in 20 patients with those of septal myectomy in 24 patients. 53 Patients who underwent myectomy were younger than those who had ablation. There was 1 death in each group. Although improvements in LVOT gradient and New York Heart Association (NYHA) class were similar in the 2 groups, the increase in maximal oxygen uptake was higher in the patients who underwent surgery.
In a fourth study, patients were triaged to ablation or surgery on the basis of age and other clinical factors. 53 The outcomes of 54 patients undergoing septal ablation were compared with those of 48 patients undergoing septal myectomy. Relief of symptoms was more complete in the surgical group. More late deaths occurred in the ablation group.
A comparison of echocardiographic indexes of diastolic function an average of 5 months after intervention demonstrated no difference between septal ablation and septal myectomy. 54
Which Patients Are Candidates for Mechanical Therapy for HOCM?
Mechanical therapy is appropriate for patients with HOCM who have symptoms (exertional dyspnea, angina, and/or "hemodynamic" syncope) that interfere significantly with lifestyle and are refractory to optimal medical therapy. The clinical threshold for performing septal ablation should be identical to that for performing septal myectomy.
Optimal therapy consists of ␤-blockade titrated to symptom relief, heart rate, or an adverse reaction. In patients with substantial symptoms despite optimal ␤-blockade, disopyramide, starting as 150 mg BID in the controlled-release form, may be added. Although disopyramide administration is sometimes limited by QT prolongation, a retrospective mul- 
Fifer Septal Myectomy Versus Septal Ablation
ticenter study provides some evidence against a proarrhythmic effect of the drug in patients with HOCM. 55 In patients with noncardiac side effects of ␤-blockade, verapamil usually is substituted. In patients without resting LVOT gradients of at least 30 to 50 mm Hg, exercise may bring out a provocable gradient. Patients with obstruction at rest or during exercise are candidates for mechanical therapy if they have symptoms that interfere substantially with their lifestyles despite truly optimal medical therapy. Published guidelines suggest that patients undergoing mechanical therapy should be in NYHA class III or IV. 56 Because patients in NYHA class II have, by definition, symptoms during ordinary physical activity, 57 some of these patients also are appropriate candidates for either septal ablation or septal myectomy. Patients in class II are, in fact, often managed with either septal ablation 36, 37, 51, 53 or septal myectomy. 20 -22,24 -26,51,53 On the other hand, some patients in NYHA class III choose to live with their symptoms rather than undergo interventional or surgical management.
Retrospective studies have suggested that prognosis in HCM is related to the presence of a resting LVOT gradient 58 and that prognosis in HOCM is favorably affected by septal myectomy. 23 In the absence of conclusive prospective data to indicate that reducing or abolishing the gradient improves prognosis, however, mechanical therapy should not be offered to patients, even those with large gradients, if they have no or mild symptoms.
In some cases, HOCM is associated with intrinsic abnormalities of the mitral valve. These and other patients who require concomitant valve surgery or coronary bypass grafting should undergo septal myectomy rather than septal ablation. Surgery also should be considered for patients with atrial fibrillation who might benefit from a concomitant maze procedure.
Advantages of Septal Myectomy
1. The success rate for septal myectomy is higher than that for septal ablation. This difference results in part from the dependence of the septal ablation procedure on the vagaries of septal anatomy. 2. Sustained relief of outflow obstruction occurs immediately after septal myectomy but may be delayed by up to 3 months after septal ablation. 3. Longer-term data are available for septal myectomy than for septal ablation, a consideration of particular relevance to the management of younger patients. 4. Although both septal myectomy after failed septal ablation and septal ablation after failed septal myectomy have been carried out successfully, the former is more common. Because septal ablation often causes right bundle-branch block and septal myectomy often causes left bundlebranch block, patients undergoing the 2 procedures in sequence incur a very high risk of complete heart block, necessitating permanent pacing. A younger patient may therefore be better served by the strategy of primary septal myectomy to avoid the prospect of decades of permanent pacing.
Advantages of Septal Ablation
1. Septal ablation has the potential for greater patient satisfaction because of absence of a surgical incision and need for general anesthesia, the lower amount of pain, and the much shorter recovery time. 2. The benefit of alcohol septal ablation in older patients is similar to that in younger patients. 36, 59 Because the risks of cardiac surgery, particularly stroke, increase with age, ablation may offer an advantage in older patients. 3. The cost of septal ablation is less than that of septal myectomy.
What We Do Not Know
1. No randomized trials have been conducted on septal ablation versus septal myectomy. 2. Conclusive data on the effect of either septal ablation or septal myectomy on life expectancy are not available. 3. Although it is clear that life-threatening ventricular tachyarrhythmias after septal ablation are rare, they have been reported in sporadic cases. In the absence of definitive data, a reasonable strategy is to consider septal ablation a potential risk factor for sudden death. A corollary is that patients with preexisting risk factors (recurrent syncope, family history of sudden death in association with HCM, ventricular tachycardia, severe hypertrophy, or abnormal blood pressure response to exercise) should be considered for implantation of a cardioverter-defibrillator before septal ablation. 4. The first septal ablation was performed in 1994; thus, long-term follow-up data in substantial numbers of patients are not available. 5. Studies comparing the cost-effectiveness of septal ablation and septal myectomy have not been done. 6. It is not known whether the outcomes of septal ablation and septal myectomy described at high-volume centers can be reproduced at other institutions.
Thus, although some have expressed strong, well-reasoned opinions in support of either septal ablation 60 or septal myectomy 61 as the procedure of choice, existing data are inconclusive, so the management decision in many cases depends critically on patient choice.
Application to Patient Care
Triage of patients to septal ablation or septal myectomy is illustrated by the following recent real-life cases from Massachusetts General Hospital.
Case 1: A 43-year-old man had exertional dyspnea and angina despite ␤-blockade. Septal thickness was 16 mm, and LVOT gradient 72 mm Hg. On the combination of a ␤-blocker and disopyramide, his symptoms remitted. Case 2: A 61-year-old man had severe lightheadedness and exertional dyspnea despite optimal medical therapy in association with HOCM and pulmonary fibrosis. Septal thickness was 22 mm, and LVOT gradient 116 mm Hg. Because of his pulmonary disease, the patient underwent septal ablation.
Case 3: A 27-year-old man had presyncope and progressive exertional angina and dyspnea despite optimal medical therapy. Septal thickness was 26 mm, and LVOT gradient 184 mm Hg. His symptoms were refractory to medical therapy. Because of his young age and marked hypertrophy, the patient underwent septal myectomy.
Case 4: A 73-year-old woman had severe bisided heart failure in association with HOCM and chronic obstructive pulmonary disease. Septal thickness was 24 mm, and LVOT gradient 121 mm Hg. Diuresis was limited by hypotension and azotemia. Because she was in need of immediate relief of outflow obstruction and despite her concomitant pulmonary disease, the patient underwent septal myectomy.
Case 5: A 46-year-old woman had disabling angina, dyspnea, and lightheadedness despite optimal medical therapy. Septal thickness was 19 mm, and LVOT gradient 121 mm Hg. Both mechanical options-septal ablation and septal myectomy-were offered to the patient.
For patients like the last one, clinical decision making is not informed by clear-cut data demonstrating that either septal ablation or septal myectomy is superior. For such "gray-area" patients, the principle of patient autonomy dictates that it is appropriate for the properly informed patient to choose between the 2 procedures.
What to Tell Patients
Patients' decisions depend critically on the information given to them by their physicians and the manner in which it is presented. To enable the patient to make what for him or her is the best decision, the physician must present a thorough and objective comparison of the 2 procedures. The physician must recognize that local outcomes for either septal ablation or septal myectomy may not match those from high-volume centers. For example, the incidence of heart block for which permanent pacing is indicated may be higher for both procedures than that reported from a few select centers. All percentage estimates should be modified accordingly. Representative considerations to communicate to patients are the following:
1. The medium-term success rate for septal myectomy (Ϸ90% to 95%) is higher than that for septal ablation (Ϸ80% to 90%). 2. Clinical benefit is realized immediately after recovery from septal myectomy but may be delayed for up to 3 months after septal ablation.
3. Neither the long-term success rate for septal ablation nor the long-term consequences of the septal ablation scar is known. 4. The mortality rates of the 2 procedures (in otherwise healthy patients) are comparable (Ϸ1% to 2%). 5. The chance of needing a permanent pacemaker is much higher after septal ablation (Ϸ10% to 15%) than after septal myectomy (Ϸ5%). 6. Although it is possible to have septal myectomy after failed septal ablation, the likelihood of needing a permanent pacemaker is extremely high after that sequence. 7. In older patients, the chance of having a stroke is lower with septal ablation than with septal myectomy. 8. The recovery time after septal myectomy is much longer than that after septal ablation.
What Patients Will Choose
Cardiologists and their patients are confronted by the choice between percutaneous transcatheter and surgical therapies much more often in coronary artery disease than in HOCM. In the setting of coronary artery disease, most, but not all, patients for whom either procedure would be appropriate choose percutaneous coronary intervention over coronary artery bypass grafting. The choice appears to be motivated by substantial value placed by the patient in the avoidance of the incision, general anesthesia, pain, and/or long recovery associated with surgery. These factors also have engendered extension of nonsurgical interventional procedures to the management of congenital and valvular cardiac lesions. Similarly, and for the same reasons, most gray-area patients with HOCM choose septal ablation over septal myectomy. Patients are of course influenced by the information presented to them by physicians. It is important to emphasize that not all patients fall into the gray area; as illustrated above by the case examples, many patients exist for whom the cardiologist should direct the management to either septal ablation or septal myectomy. It is also critical that gray-area patients be allowed to choose between the options in an unhurried, unpressured environment and to seek counsel from family, friends, other patients with HCM, and other physicians.
Conclusions
Longer-term follow-up will permit judgment on the durability of the medium-term amelioration of LVOT gradient and improvement in symptoms observed in most patients after septal ablation. No data exist to support extending the current indications for mechanical management of HOCM to patients with only mild symptoms. If cardiologists adhere to strict inclusion criteria for septal ablation and septal myectomy, with either procedure performed only in patients with symptoms that interfere substantially with their lifestyles and are refractory to truly optimal (usually
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Septal Myectomy Versus Septal Ablation 2-drug) medical therapy, few centers offering the procedures are likely to maintain reasonable minimum case volumes. Operators performing the procedures at lower rates may have lower success and higher complication rates. Accordingly, performance of both septal ablation and septal myectomy should be confined to regional referral centers. The mechanical procedures should be offered only in the context of a program that integrates expertise in all aspects of HCM, including genetic counseling and arrhythmia management. Future comparisons of the results of septal ablation and septal myectomy would be aided by adoption of a standard definition of success of the procedures. One possible definition would be improvement by Ն1 NYHA or Canadian Cardiovascular Society class and gradient reduction by Ն50% at 3 months after the procedure. Clinical equipoise would allow performance of a multicenter randomized trial comparing septal ablation and septal myectomy. 62, 63 Because mortality is low after both procedures, selection of a primary end point such as exercise capacity is advisable.
